▎CJC1295 No DAC Research
What is the research background of CJC1295 no DAC?
Growth hormone-releasing hormone (GHRH) is used in treatment to enhance the secretion of growth hormone (GH), but it has a major limitation, that is, its short duration of action[1]. This limits the widespread clinical application of GHRH and prompts researchers to seek more long-acting alternatives. CJC1295 no DAC is a peptide drug based on 30 amino acids. It can stimulate the pituitary gland to release growth hormone (GH). This peptide drug is different from traditional peptide drugs. Its uniqueness lies in the presence of a reactive maleimide propionic acid group, which can covalently bind to the free thiols on the surface of plasma proteins. Once bound to plasma proteins, the active time of CJC1295 no DAC in the blood is significantly prolonged. Compared with unbound peptide drugs, those unbound peptide drugs will be rapidly excreted from the body, while the bound CJC1295 no DAC can remain active in the blood for a longer time. This binding mechanism makes CJC1295 no DAC a drug with a special effect.
What is the mechanism of action of CJC1295 no DAC?
Stimulating the pituitary gland to release growth hormone: This drug can stimulate the pituitary gland to release growth hormone (GH). When CJC1295 no DAC enters the body, it acts on the pituitary gland through a specific mechanism, prompting pituitary cells to increase the secretion of GH. Specifically, it may bind to specific receptors on the surface of pituitary cells, initiating a series of signal transduction pathways, ultimately leading to an increase in the synthesis and release of GH [1, 2].
Binding to plasma proteins: CJC1295 no DAC has a unique feature, that is, there is a reactive group in its structure, which can covalently bind to the free thiols on the surface of plasma proteins. This binding significantly prolongs the time that the drug remains active in the blood. Compared with unbound peptide drugs, the bound CJC1295 no DAC has a longer half-life [2]. Some studies have shown that CJC-1295 incorporates a functional maleimide group at the C-terminus, allowing it to covalently bind to plasma proteins such as serum albumin. Once bound, it can stimulate GH production in humans for more than six days after a single administration (Timms M, 2019, a).
Increasing the secretion of growth hormone: After a single injection of CJC1295 no DAC, it will lead to a dose-dependent increase in the average plasma GH concentration. This increase can last for 6 days or longer, with an increase range of 2 to 10 times [2-4]. In a study, after healthy adults received a subcutaneous injection of CJC-1295, there was a continuous, dose-dependent increase in GH levels. The estimated half-life of CJC-1295 was 5.8 - 8.1 days (Teichman S L, 2006). In GHRH knockout (GHRHKO) mice, similar properties were also shown. Daily administration of CJC1295 can maintain normal body composition and growth[5].
Affecting the secretion of insulin-like growth factor I: CJC1295 no DAC will also affect the secretion of insulin-like growth factor I (IGF-I). The average plasma IGF-I concentration will increase in a dose-dependent manner, with an increase range of 1.5 to 3 times, and the duration is 9 - 11 days [2-4]. After multiple administrations of the CJC1295 no DAC dose, the average IGF-I level remains higher than the baseline level for up to 28 days (Teichman S L, 2006). In GHRHKO mice, CJC1295 also caused an increase in total pituitary RNA and GH mRNA, indicating the proliferation of growth hormone-secreting cells[5].
![2]( "2")
Plasma disappearance curves of CJC-1295 after a single sc injection. Shown are the mean SD half-life.
Source:PubMed[1]
What are the differences in the treatment mechanisms of CJC1295 no DAC for patients with growth hormone deficiency of different age groups?
Child patients: Children are in a critical period of growth and development, and growth hormone plays a crucial role in the growth and development of their bones, muscles, and organs. Growth hormone deficiency can lead to problems such as slow growth, short stature, and delayed bone age in children.
CJC1295 no DAC promotes the growth and development of children by stimulating the pituitary gland to secrete growth hormone. It can increase the secretion amount and duration of growth hormone, and raise the levels of growth hormone and insulin-like growth factor - I (IGF-I) in the serum[3]. IGF-I is the main mediator of the action of growth hormone. It can promote cell proliferation, differentiation, and protein synthesis, and has an important role in the growth and development of bones, muscles, and organs. CJC1295 no DAC can also promote the increase of bone diabetes indicators such as osteocalcin and alkaline phosphatase, which is helpful for the growth and mineralization of bones. In addition, CJC1295 no DAC has no obvious effect on thyroid function and has a high safety level.
Adult patients:
Adult patients with growth hormone deficiency may experience problems such as decreased muscle mass, increased fat, decreased physical strength, increased risk of cardiovascular diseases, and osteoporosis. Compared with child patients, the growth and development of adult patients have been basically completed, and the focus of treatment is on improving metabolic function and quality of life. The treatment mechanism of CJC1295 no DAC in adult patients is mainly to improve muscle strength, reduce fat mass, improve heart function, delay aging, and prevent osteoporosis by increasing the levels of growth hormone and IGF-I. Studies have shown that CJC1295 no DAC can increase the lean body mass of adult patients, reduce subcutaneous fat mass, improve insulin sensitivity, and reduce the risk of cardiovascular diseases. In addition, CJC1295 no DAC can also promote the growth and mineralization of bones, increase bone density, and prevent osteoporosis [3, 5].
Elderly patients:
With the increase of age, the secretion of growth hormone in the human body gradually decreases, leading to problems such as decreased muscle mass, increased fat, osteoporosis, and decreased immunity. Elderly patients with growth hormone deficiency have a higher disease risk, and the treatment is more difficult. The treatment mechanism of CJC1295 no DAC in elderly patients is similar to that in adult patients, but the dosage needs to be adjusted more carefully and adverse reactions need to be monitored. Due to the decline of the physical functions of elderly patients and the weakened ability to metabolize and excrete drugs, the dosage of the drug needs to be reduced to avoid drug accumulation and the occurrence of adverse reactions.
Related research
What are the effects of CJC1295 no DAC?
Promoting the secretion of growth hormone:
As an analogue of growth hormone-releasing hormone (GHRH), CJC1295 no DAC can bind to the GHRH receptors in the anterior pituitary gland and stimulate the synthesis and secretion of growth hormone by growth hormone cells. Growth hormone is crucial for the body's growth and development, diabetes, and tissue repair processes. In some studies, after using CJC1295 no DAC, an increase in the level of growth hormone in the blood can be observed, which helps to promote the growth and repair of tissues such as bones and muscles.
Regulating diabetes:
Growth hormone plays a key role in the regulation of diabetes. CJC1295 no DAC indirectly affects the metabolic process by promoting the secretion of growth hormone. It can promote fat breakdown, making fat be used as an energy source, which helps to reduce the storage of fat in the body and improve the body's fat distribution. At the same time, it can also promote protein synthesis, increase the deposition of protein in muscle tissues, which helps to improve muscle quality and strength, and enhance the body's exercise ability and endurance. In addition, CJC1295 no DAC also has a certain impact on glucose diabetes, and may increase insulin sensitivity, which helps to maintain normal blood glucose levels.
Promoting tissue repair and regeneration:
Growth hormone plays an important role in the repair and regeneration of damaged tissues. CJC1295 no DAC promotes the secretion of growth hormone, which in turn stimulates cell proliferation and differentiation, accelerates wound healing, and promotes the repair of damaged tissues. In some animal experiments and clinical studies, it has been found that it is helpful for fracture healing, muscle injury repair, and skin wound healing, etc., and has potential significance for improving the body's recovery ability and restoring the function of damaged tissues.
What are the application fields of CJC1295 no DAC?
Treatment of growth hormone deficiency:
For patients with growth hormone deficiency, CJC-1295 Without DAC can stimulate the secretion of growth hormone, thus promoting the growth and development of the body. It may provide a new treatment option for those patients who have poor response to traditional growth hormone treatment[3].
Regulation of metabolic disorders:
Growth hormone plays an important role in regulating the body's metabolic process. CJC-1295 Without DAC can improve insulin resistance, regulate fat diabetes, etc. by increasing the secretion of growth hormone, and may have certain therapeutic potential for metabolic disorders such as diabetes and obesity[3].
Skin rejuvenation:
Growth hormone can promote the synthesis of collagen, increase skin elasticity, and reduce wrinkles. CJC-1295 Without DAC may achieve skin rejuvenation by stimulating the secretion of growth hormone[6].
Improving physical function:
With the increase of age, various functions of the body will gradually decline. Growth hormone can increase muscle strength, improve bone density, and enhance immunity, etc. CJC-1295 Without DAC may help to delay the aging process and improve the quality of life of the elderly[3].
Increasing muscle strength:
Growth hormone can promote protein synthesis and increase muscle mass. For athletes and fitness enthusiasts, CJC-1295 Without DAC may help to improve muscle strength and endurance[6].
Promoting exercise recovery:
After high-intensity exercise, the body needs time to recover. Growth hormone can accelerate the repair of damaged tissues and reduce the inflammatory response. CJC-1295 Without DAC may help to shorten the recovery time after exercise and improve exercise performance [3].
Anti-aging:
With the increasing attention to anti-aging, CJC1295 no DAC is also considered by some people to have the potential of anti-aging. Growth hormone and IGF-I play an important role in maintaining the normal physiological functions of the body and tissue repair. Therefore, this substance may have an impact on the aging process by regulating these factors [3].
As an analogue of growth hormone-releasing hormone, CJC1295 no DAC has significant effects. It can stimulate the pituitary gland to release growth hormone, regulate the secretion of insulin-like growth factor I, and thus affect the growth and diabetes of the body. In scientific research, it provides key assistance for exploring the mechanism of action of growth hormone and promotes the progress of relevant theories. In clinical applications, for patients with growth hormone deficiency, it is expected to stimulate the secretion of endogenous growth hormone and improve growth and development and metabolic abnormalities. It also shows the potential to regulate hormone levels and combat aging changes in anti-aging research. Overall, it is of great significance in both scientific research and clinical fields, bringing new opportunities for related research and disease treatment.
About The Author
The above-mentioned materials are all researched, edited and compiled by Cocer Peptides.
Scientific Journal Author
Teichman S L is an expert with rich experience and influence in the fields of medicine and drug development. He has close cooperation with many well-known institutions and enterprises, including Organizations Concentr Analges Inc, Teichman Drug Dev Consulting, Wroclaw Medical University, BEAT Biotherapeut Corp, Corthera Inc and its affiliated company Corthera, Chiasma, ARYx Therapeut Inc, etc. In addition, he is also associated with academic institutions such as the University of Athens Hospital and the Albert Einstein College of Medicine, which indicates that he has a deep background in medical research and clinical practice. His professional fields cover multiple aspects such as the cardiovascular system and cardiology, general internal medicine and general practice, engineering, endocrinology and diabetes, and pharmacology and pharmacy, especially with remarkable achievements and contributions in drug development and biotherapy. Teichman S L is listed in the reference of citation [1].
